Jerry C. Griffin - 01 Mar 2024 Form 4 Insider Report for Inspire Medical Systems, Inc. (INSP)

Role
Director
Signature
/s/ Bryan Phillips, as Attorney-in-Fact for Jerry C. Griffin
Issuer symbol
INSP
Transactions as of
01 Mar 2024
Net transactions value
-$83,410
Form type
4
Filing time
05 Mar 2024, 17:08:02 UTC
Previous filing
01 Aug 2023
Next filing
13 Mar 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSP Common Stock Options Exercise $16,000 +1,000 +11% $16.00 9,852 01 Mar 2024 Direct
transaction INSP Common Stock Sale $9,690 -54 -0.55% $179.44 9,798 01 Mar 2024 Direct F1
transaction INSP Common Stock Sale $89,720 -500 -5.7% $179.44 8,298 01 Mar 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSP Stock Option (Right to Buy) Options Exercise $0 -1,000 -23% $0.000000 3,296 01 Mar 2024 Common Stock 1,000 $16.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reflects shares sold to cover taxes upon the option exercise pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 30, 2023 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F3 The option is fully vested and exercisable.